tbuckley/cabot-search huggingface dataset:
Comparative study of therapy-related (tALL) and de novo adult acute lymphoblastic leukemia (dnALL): Contemporary Mayo Clinic ALL cohort.
Authors: Zaid Abdel Rahman, Ricardo Daniel Parrondo, Michael Heckman, Matthew Spiegel, Kevin Charles Miller, Lisa Ostrosky Sproat, Liuyan Jiang, Hemant S. Murthy, Hassan Alkhateeb, Mark Robert Litzow, Patricia T. Greipp, James M. Foran
Journal: Journal of Clinical Oncology (2020)

7523 Background: tALL is a recently appreciated but poorly defined clinical entity. We define tALL as any prior exposure to cytotoxic chemotherapy and/or radiation for another malignancy, and we report a comparative analysis of characteristics, cytogenetics and outcomes for this subset among a modern unselected ALL cohort from the Mayo Clinic Cancer Center (MCCC). Methods: We performed a systematic search in the 3-site MCCC registry and included all patients (pts) diagnosed and received at least 1 cycle of ALL-directed therapy and/or underwent allogeneic transplantation (AlloHCT) between 2008-2018. Comparisons of characteristics between tALL and dnALL were made using a Wilcoxon rank sum test (continuous variables) and Fisher’s exact test (categorical variables). Time-to-event variables were compared using unadjusted Cox proportional hazards regression models. Results: 431 ALL pts were identified during the study period, including n = 69 (16%) classified as tALL. Median follow-up from diagnosis was 2.3 years (range 0-18 years). The most common prior malignancies among tALL pts were Breast (24.6%), Lymphoma (15.9%), Myeloid (15.9%), GU/GYN (14.5%) and Myeloma (11.6%). In comparison to dnALL, pts with tALL were significantly older (63.2 vs 45.2 years, P &lt; 0.001), more often female (65.2% vs 39.8%, P &lt; 0.001), less frequently Hispanic (3.5% vs 13.1%, P = 0.042); more often of B-lineage (92.8% vs 81.8%, P = 0.022). On review of cytogenetics, tALL pts more often had hypodiploidy/near triploidy (Ho/Tr) (21.7% vs 4.1%, P &lt; 0.001), more often had monosomal (MDS-like) (33.3% vs 12.4%, P = 0.0047) and complex karyotype (38% vs 17.3%, P = 0.0069). Importantly, incidence of BCR/ABL-positive (Ph+) ALL was not significantly different. Latency period between exposure to prior cancer therapy and development of tALL was significantly longer for Ph+ compared to Ph-negative ALL (median 9 vs. 4 years, P = 0.007). Patients with tALL had a 3-year OS after diagnosis of 37% [vs 59.7% for dnALL (HR death 1.86, 95% CI 1.31-2.65, P &lt; 0.001)]. However, the two groups did not differ significantly regarding occurrence of AlloHCT (HR = 0.91, 95% CI 0.63-1.31, P = 0.61) or post-AlloHCT survival (HR = 1.29, 95% CI 0.75-2.23, P = 0.35). Conclusions: Therapy-related ALL represents an important &amp; unique clinical entity with poor prognosis &amp; adverse cytogenetic features. Ph+ tALL has a longer latency and similar frequency in both tALL and dnALL. AlloHCT appears to be an appropriate treatment strategy, possibly abrogating the poor prognosis of tALL.
丹参和低分子肝素联合治疗肺源性心脏病急性加重期患者效果分析
Authors: 裴晶, 林殿杰
Journal: BMJ (2012)

将65例慢性肺源性心脏病急性加重期患者分为常规治疗和联合丹参及低分子肝素治疗两组,治疗前后两组血抗凝血酶Ⅲ、纤维蛋白原及平均肺动脉压水平的差异有统计学意义,两组临床疗效差异亦有统计学意义.说明在常规治疗基础上加用低分子肝素及注射用丹参可显著改善凝血分子标志物水平,降低肺动脉高压,提高临床疗效。
Patient enablement and its related factors in family medicine clinic of a general hospital
Authors: Ruihong Liu, Lujuan Lin, Zhuo Li, Qinqi Chen, Yizhen Jia, Zhiwei Huang
Journal: BMJ (2017)

Objective
To assess the patient enablement level in a general hospital and its related factors, to investigate the relationship of patient enablement with patient′s overall satisfaction and doctor′s empathy levels.


Methods
Patients attending the Family Medicine Clinic of HKU-Shenzhen Hospital in September 2014 and met the inclusion criteria were asked to complete a questionnaire survey which included general characteristics, overall satisfaction; the Patient Enablement Instrument (PEI) and the Consultation and Relational Empathy Measure Scale (CARE) after the consultation.


Results
Total 2 326 questionnaires were issued and 1 818 were retrieved, of which 1 478 were qualified questionnaires. The qualified rate of PEI was 81.3% and the qualified rate of patient overall satisfaction was 96.28%. The positive rate of patient enablement was 97.70% (1 444/1 478), and the mean score of PEI was 8.21±3.33. Multivariate linear regression analysis showed that the PEI scores were not influenced by gender and education level of the patients, gender of the consulting doctors and initial/follow up consultation. The PEI scores were influenced by the age of the patients, the types of clinic (general practice/chronic practice clinic) and the reasons for consulting (P<0.05). There were correlations between PEI score and overall satisfaction of patients (r=0.383, P<0.001), patient′s recommendation of the clinic (r=0.595, P<0.001)and CARE scores (r=0.546, P<0.001).


Conclusion
The results show that the PEI scores of patients visiting family medicine clinic of this hospital are higher than those reported in other studies. The PEI score may be influenced by the age of the patients, the types of clinic and the reasons for consulting. Positive correlations between patient enablement and the overall satisfaction, patient′s recommendation and doctor empathy were observed.


Key words: 
Questionnaires; Patient enablement; General practitioners
强阳胶囊治疗功能性勃起功能障碍的临床观察
Authors: 荀建宁, 朱闽
Journal: BMJ (2010)

勃起功能障碍(erectile dysfunction,ED)是指男子在性刺激下,持续地(6个月以上)不能达到或维持足够硬度的阴茎勃起以完成满意性交~([1]).据统计,40～70岁的男性中有52%存在着不同程度的ED~([2]).自2005年6月至2009年1月,本研究使用强阳胶囊治疗肾阳虚型ED,取得了较好的临床疗效,现报告如下。
The choice on rate control and rhythm control in patients with atrial fibrillation and heart failure
Authors: 郑刚
Journal: BMJ (2009)

心房颤动(房颤)往往是心力衰竭(心衰)患者的一个最常见的并发症.心衰是发生房颤的独立危险因素,房颤可造成心房和心窜收缩和舒张不同步,使心室舒张时间缩短,导致心衰加重和病情恶化.目前房颤的药物治疗策略通常采用复律并用抗心律失常药物维持窦性心律(节律控制或心律控制)或控制心室率并长期抗凝治疗(频率控制或心室率控制)两大类….两种治疗方法对心衰合并房颤的患者主要终点死亡的影响是否存在差异,是近年临床医学关注的热点.现应用循证医学观点,用临床试验的结果对心衰合并房颤的节律控制和频率控制进行系统的分析和比较。
Vitamin D supplements and marine omega-3 fatty acids and development of advanced cancer.
Authors: Paulette Chandler, Wendy Y. Chen, Oluremi Ajala, Aditi Hazra, Nancy Cook, Vadim Bubes, I-Min Lee, Edward L. Giovannucci, Julie Buring, JoAnn E Manson
Journal: Journal of Clinical Oncology (2020)

1510 Background: Epidemiologic data suggest that vitamin D supplementation may reduce cancer mortality. We tested whether vitamin D and/or omega-3 supplementation reduces the incidence of advanced stage cancer at diagnosis or lethal cancer, and whether body mass index (BMI) modifies these associations. Methods: The VITamin D and OmegA-3 TriaL (VITAL) is a randomized, placebo-controlled, 2x2 factorial trial of vitamin D3 (cholecalciferol, 2000 IU/day) and marine omega-3 fatty acids (1 g/day) that enrolled men aged ≥50 years and women aged ≥55 years free of cancer and cardiovascular disease at baseline. For this particular analysis, the primary outcome is a composite of metastatic and fatal invasive total cancer. Secondary analyses included examination of BMI (&lt;25, 25-&lt;30, and &gt;= 30 kg/m 2 ) as effect modifiers of the observed associations. Results: VITAL randomized 25,871 participants, among whom 1,617 were diagnosed with invasive cancer over a median 5.3 year intervention period. No significant differences by treatment arm (vitamin D vs placebo: hazard ratio [HR]=0.96; 95% confidence interval, 0.88-1.06; p=0.47; omega-3 vs placebo; HR 1.03 [0.93-1.13]; p=0.56) were observed. However, a significant reduction in advanced cancers (metastatic or fatal) was found for those randomized to vitamin D, compared to placebo (226 assigned to vitamin D and 274 to placebo; HR 0.83 [0.69-0.99]; p=0.036). There was no difference by omega-3 assignment (246 assigned to omega-3 and 254 to placebo: HR 0.97 [0.81-1.15], p=0.72). When stratified by BMI, there was a significant reduction for the vitamin D arm in incident metastatic or fatal cancer among those with normal BMI (BMI&lt;25: HR 0.62 [0.45-0.86], but not among those who were overweight or obese (BMI 25-&lt;30: HR 0.89 [0.68-1.17]; BMI &gt;=30: HR 1.05 [0.74-1.49]); p for interaction by BMI =0.03. There was no effect modification by BMI noted for the omega 3 arm. Conclusions: In a randomized clinical trial, supplementation with vitamin D, but not omega-3s, reduced incidence of advanced (metastatic or fatal) cancer in the overall cohort, with strongest risk reduction in normal weight individuals. Further research is needed to understand these findings. Clinical trial information: NCT01169259.
Prognostic value of programmed death-ligand 1 in solid tumors: A meta-analysis.
Authors: Jordan L Scott, Michelle Nadler, Alexandra Desnoyers, Fahad Almugbel, Rouhi Fazelzad, Eitan Amir, Ramy Saleh
Journal: Journal of Clinical Oncology (2020)

e19121 Background: The programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway plays a crucial role in cancer immuno-surveillance and is the target of approved immunotherapeutic drugs. Available data suggest a variable prognostic impact of PD-L1 expression in solid tumors. Methods: A systematic literature search of electronic databases identified publications exploring the effect of PD-L1 on overall survival (OS) and/or progression-free survival (PFS). Hazard ratios (HR) were pooled in a meta-analysis using generic inverse-variance and random effects modeling. Subgroup analyses were conducted based on disease site, stage of disease, and method of PD-L1 quantification using the Deeks method. Results: One hundred eighty-eight studies comprised of 212,748 patients met the inclusion criteria. PD-L1 expression was associated with worse OS (HR 1.32, 95% confidence interval (CI) 1.25 - 1.38; P &lt; 0.001). There was significant heterogeneity between disease sites (subgroup P = 0.002) with pancreatic, hepatocellular and genitourinary cancers being associated with the highest magnitude of adverse outcome (Table). PD-L1 was also associated with worse overall PFS (HR 1.19, 95% CI 1.09 - 1.30; P &lt; 0.001). Stage of disease did not significantly affect the results (subgroup P = 0.52), nor did the method of quantification (immunohistochemistry or mRNA) (subgroup P = 0.70). Conclusions: High expression of PD-L1 is associated with worse cancer outcomes albeit with significant heterogeneity between disease sites. The effect seems consistent in early stage and metastatic disease and is not sensitive to method of PD-L1 quantification. [Table: see text]
发热-咳嗽-贫血-血小板减少-胸痛
Authors: 蒋婉岚, 范俊平, 沈敏, 曾学军
Journal: BMJ (2012)

患者女,17岁,因反复发热半年,咳嗽、咳痰10d于2011年9月5日入我院2011年2月,患者无明显诱因出现发热,最高体温39.0℃,多于午后达峰,无畏寒、寒战,伴头痛、乏力、盗汗.于当地医院抗生素(具体不详)治疗数日后症状可缓解,但数日或数周后再发入院前10天病情复发,并出现刺激性咳嗽,咯少量黄黏痰,伴肢端可凹性水肿,无胸闷憋气我院门诊查血常规: 关键词：心内膜炎;细菌性
A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity
Authors: Marthe C. J. Roex, Lois Hageman, Sabrina A. J. Veld, Esther van Egmond, Conny Hoogstraten, Christian Stemberger, Lothar Germeroth, Hermann Einsele, J. H. Frederik Falkenburg, Inge Jedema
Journal: Blood (2020)
Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Authors: Martin Hutchings, Pieternella Lugtenburg, Rogier Mous, Michael Roost Clausen, Martine Chamuleau, Kim Linton, Simon Rule, Juanita Suzanne Lopez, Roberto S Oliveri, Dena DeMarco, Brian Elliott, Peter Johnson
Journal: Journal of Clinical Oncology (2020)

8009 Background: CD3×CD20 bispecific antibodies (bsAbs) have demonstrated promising results for the treatment of pts with R/R B-NHL. Epcoritamab is a novel subcutaneously administered bsAb with a favorable safety profile and encouraging preliminary anti-tumor activity at low doses in both aggressive and indolent B-NHL. Here we present updated safety and efficacy data from the ongoing trial (NCT03625037). Methods: Adults with R/R CD20+ B-NHL received a single SC injection of flat-dose epcoritamab in 28-day cycles (q1w: cycle 1–2; q2w: cycle 3–6; q4w thereafter) until disease progression or unacceptable toxicity. Primary objectives are determination of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Secondary objectives include anti-tumor activity. Results: As of 8 Jan 2020, 41 pts with median age of 66 (range: 21–82) were enrolled. Most pts had DLBCL/HGBCL (73%) or FL (20%) and received a median (range) of 3 (1–6) and 5 (2–18) prior lines of treatment. No DLTs were observed (median follow-up: 4.7 mo; range: 3.7– 5.6). MTD has not been reached. Most common TEAEs (&gt;35%) were pyrexia (71%), fatigue (46%), and injection site reaction (39%; all Gr 1). AEs of special interest included cytokine release syndrome (59%; all Gr 1/2; all resolved) and cytokine release-related decreased CARTOX-10 score (n=1). There was no clinical tumor lysis syndrome or treatment-related deaths. Treatment is ongoing in 13 pts. Anti-tumor activity was observed at minimal efficacy threshold (based on PK modelling) for DLBCL/HGBCL and FL (Table). Complete dose escalation data and RP2D will be presented. Conclusions: SC epcoritamab continues to demonstrate a favorable safety profile across all doses with no ≥Gr 3 CRS and no DLTs. Dose escalation data show improved efficacy as doses reach above the modeled predicted exposure threshold, inducing CRs in heavily pretreated DLBCL pts. All pts achieving CRs remain in remission. Clinical trial information: NCT03625037 . [Table: see text]
Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic non-small cell lung cancer (NSCLC): CheckMate 568 Part 2.
Authors: Justin F. Gainor, Jeffrey Gary Schneider, Martin Gutierrez, James Michael Orcutt, Gene Grant Finley, Gregory Alan Otterson, Igor I. Rybkin, Pavan S. Reddy, Leora Horn, Julie R. Brahmer, Bruno R. Bastos, Mark M. Awad, Matthew David Hellmann, Suresh S. Ramalingam, Neal E. Ready, David R. Spigel, Ravi S. Kasinathan, Cécile Dorange, Hossein Borghaei
Journal: Journal of Clinical Oncology (2020)

9560 Background: In Part 1 of the phase II CheckMate 568 study (NCT02659059), NIVO + IPI was active and tolerable in patients (pts) with advanced NSCLC. The addition of chemo to dual immune checkpoint inhibitor therapy may further improve initial disease control. We report results from Part 2 of CheckMate 568, which evaluates NIVO + IPI combined with 2 cycles of chemo in pts with advanced treatment-naive NSCLC. Methods: Adult pts with untreated stage IV NSCLC received NIVO 360 mg Q3W + IPI 1 mg/kg Q6W combined with 2 cycles of histology-based platinum-doublet chemo, followed by NIVO + IPI without chemo until disease progression/unacceptable toxicity for ≤ 2 years. The primary endpoints were dose-limiting toxicity (DLT) within the first 9 weeks and safety/tolerability. Treatment was considered safe if ≤ 25% of at least 22 evaluable pts had a DLT. DLTs included but were not limited to: uncontrolled grade 3 non-skin treatment-related adverse events (TRAEs), grade 4 TRAEs, grade 2 treatment-related pneumonitis not resolved within 14 days, and treatment-related hepatic function abnormalities. Results: In total, 36 pts received treatment; 97% of pts completed 2 cycles of chemo combined with NIVO + IPI. Three pts discontinued IPI while continuing NIVO. Minimum follow-up was 14.9 months. Only 1 (3%) pt experienced a DLT (transient, asymptomatic grade 3 AST and ALT elevation) within the first 9 weeks. The elevation occurred on cycle 1, day 21 and resolved 2 weeks later with discontinuation of IPI, delay of NIVO, and treatment with prednisone; chemo was continued throughout and NIVO was restarted thereafter without recurrent toxicity. Grade 3–4 TRAEs occurred in 21 (58%) pts. Eight (22%) pts experienced a TRAE leading to discontinuation, most commonly colitis, encephalopathy, pneumonitis, and arthralgia (each in 2 [6%] pts); these events occurred outside of the 9-week window for DLT assessment. The most common select TRAEs (defined as AEs of potential immunologic causes) were skin related (18 [50%] pts); the most common grade 3–4 select TRAEs were endocrine (3 [8%] pts), skin related, gastrointestinal, and pulmonary (each in 2 [6%] pts). No treatment-related deaths occurred. Updated safety in addition to efficacy data will be presented. Conclusions: In pts with untreated advanced NSCLC, the addition of 2 cycles of platinum-doublet chemo to NIVO + tumor-optimized IPI was tolerable. No unexpected safety signals were observed. Clinical trial information: NCT02659059 .
Lavement of balsalazide sodium combined with Xileisan in treatment of ulcerative rectitis
Authors: Yang Shi, Li Wang
Journal: BMJ (2011)

Thirty patients with ulcerative rectitis were treated by lavement of balsalazide sodium solution combined with Xileisan (test group).The results were compared with those treated by salazosulfapyridine (SASP) suppository (control Ⅰ group, n = 25 ) and those treated by lavement of prednisolone and tinidazole (control Ⅱ group, n =28).The complete remission rate and effective rate were 67% (20/30)and 90% (27/30), 36% (9/25) and 60% (15/25), 68% (19/28) and 86% (24/28) for test group, control Ⅰ group and control Ⅱ group, respectively.The efficacy of test group and control Ⅱ group was better than that of control Ⅰ group (P ＜ 0.05).The least side effects occurred in test group ( P ＜0.05).The recurrence rates of 3 groups were 20% (4/20), 2/9 and 5/19, respectively.Lavement of balsalazide sodium solution combined with Xileisan is effective for ulcerative rectitis with less side effects.

Key words: 
Proctitis;  Balsalazide
Importance of the “thinking through other minds” process explored through motor correlates of motivated social interactions
Authors: Harold Mouras
Journal: Behavioral and Brain Sciences (2020)

Abstract We wanted to gather recent results supporting the idea of the central role of sharing agency in socioaffective and motivational information processing. Here, we want to support the idea that this process is quite arbitrary, early in the temporal chain of processes and not only influence the psychological, but also the motor correlates of socioaffective information processes.
Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients.
Authors: Erica Villa, Fabio Piscaglia, Rabit Geva, George Dalecos, George Papatheodoridis, Marina Ciomei, Christina Davite, Patrizia Crivori, Vaseem Palejwala, Jules Jacob, Fayez Hamzeh, Kunwar Shailubhai, Armando Santoro, Angelo Sangiovanni
Journal: Journal of Clinical Oncology (2020)

e16711 Background: Current hepatocellular carcinoma (HCC) therapeutics, tyrosine kinase inhibitors (TKI) and checkpoint inhibitors (CI), provide limited improvement in overall survival, suggesting the need to identify drugs with broad-spectrum mechanisms of action, used alone or in combination with a TKI or CI. Milciclib, a pan cyclin dependent kinase inhibitor, exhibited anti-cancer activity in refractory solid malignancy patients. The primary objective of this trial was to evaluate safety and tolerability of milciclib in sorafenib-refractory or intolerant advanced HCC patients. Methods: Single arm and multi-center study in advanced HCC patients was conducted in Italy, Greece and Israel. Milciclib was administered orally for up to 6 cycles. Each cycle consisted of 100mg milciclib daily for 4d on/3d off/week for 4 weeks. Safety assessment was the primary endpoint and secondary endpoints included progression free survival (PFS), time to progression (TTP) and clinical benefit rate (CBR). Results: A total of 31 patients were enrolled and 28 were evaluable for efficacy, of which 14 (50%) completed 6-months of treatment. Milciclib was well-tolerated with manageable toxicities. Eighteen of 31 treated patients had drug-related adverse events (AEs) with most frequent (≥5%) occurrence of drug-related diarrhea, nausea, asthenia, fatigue, retinal hemorrhage, rash and myalgia. No drug-related deaths were recorded. Nine of 14 patients (64%) continued treatment under Compassionate Use after study completion. Seven patients received milciclib until 9, 9, 10, 11, 13, 13 and 16 months. The remaining 2 patients are in the 16 th month of treatment. Clinical response to treatment, assessed by mRECIST (independent radiological review), is shown in the Table. Both median TTP and PFS were 5.9 months. Conclusions: Milciclib, acting via a new mechanism, was safe, well-tolerated and met primary and secondary endpoints with 61% CBR. These promising clinical data warrant further evaluation of milciclib. Clinical trial information: NCT03109886 . [Table: see text]
Changes of urodynamics in female patients with diabetic cystopathy
Authors: Zhiqing Ding, Yu Qian, He Jiang, Yang Jiang, Wei Jia
Journal: BMJ (2014)

Objective
To evaluate the changes of urodynamics in female patients with diabetic cystopathy.


Methods
Fifty six female patients with diabetic cystopathy were enrolled in the study, including 31 cases with diabetic course <15 years (group Ⅰ) and 25 cases with diabetic course ≥15 years (group Ⅱ) . Urodynamic examination was performed in all patients and the urodynamic parameters were compared between two groups.


Results
The average residual urine volume, the volume of first bladder sensation and the max bladder capacity in groups Ⅰ and Ⅱ were (35±16)ml and (65±24) ml, (220±76)ml and (330±88)ml, (380±92)ml and (580±122)ml, respectively; 3 out 31 and 16 out of 25 patients in groups Ⅰ and Ⅱ showed low compliance. The above indexes between two groups were statistically significant (P<0.01).


Conclusion
Urodynamics can indicate the severity of functional damage of urinary bladder in patients with diabetic cystopathy.


Key words: 
Urodynamics; Urinary, bladder, nearogenic; Diabetesmellitus; Female